Drug Profile
Research programme: peptide-based therapeutics - Johnson & Johnson Innovative Medicine/PeptiDream
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceuticals; PeptiDream
- Developer Johnson & Johnson Innovative Medicine; PeptiDream
- Class Drug conjugates; Macrocyclic compounds; Peptides; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 May 2021 No recent reports of development identified for research development in Cardiovascular-disorders in Japan
- 28 May 2021 No recent reports of development identified for research development in Metabolic-disorders in Japan